Extrahepatic bile duct carcinoma
MONDO:0003090A carcinoma that arises from epithelial cells of the extrahepatic bile duct.
Also known as: carcinoma of extrahepatic bile duct, carcinoma of the extrahepatic bile duct, extrahepatic bile duct cancer, extrahepatic bile duct carcinoma
3329 clinical trials for this condition and its sub-types, 51 tagged with Extrahepatic bile duct carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Extrahepatic bile duct carcinoma
-
Extrahepatic bile duct adenocarcinoma 2 trials · 409 incl. sub-types
7 sub-types
- Adenocarcinoma of gallbladder and extrahepatic biliary tract 6 trials · 374 incl. sub-types Sub-types →
- Ampulla of vater adenocarcinoma 11 trials · 42 incl. sub-types Sub-types →
- Extrahepatic bile duct clear cell adenocarcinoma 0 trials Sub-types →
- Extrahepatic bile duct mucinous adenocarcinoma 0 trials Sub-types →
- Extrahepatic bile duct signet ring cell carcinoma 0 trials Sub-types →
- Extrahepatic bile duct small cell adenocarcinoma 0 trials
- Papillary extrahepatic bile duct adenocarcinoma 0 trials
-
Carcinoma of the ampulla of vater 29 trials · 65 incl. sub-types
3 sub-types
- Ampulla of vater adenocarcinoma 11 trials · 42 incl. sub-types Sub-types →
- Ampulla of vater small cell neuroendocrine carcinoma 0 trials
- Ampulla of vater squamous cell carcinoma 0 trials Sub-types →
-
Distal biliary tract carcinoma 32 trials
Most studied deeper sub-types
-
New combo therapy shows promise for Tough-to-Treat bile duct cancer
Disease control OngoingThis study tests whether adding the experimental drug CTX-009 to standard chemotherapy (paclitaxel) helps adults with advanced bile duct, gallbladder, or ampullary cancer that has worsened after one prior treatment. About 168 participants will be randomly assigned to receive eith…
Phase 2/3 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New combo attack on biliary cancers: targeted drug plus chemo shows promise
Disease control OngoingThis study tests whether adding the targeted drug binimetinib to standard chemotherapy (mFOLFOX6) can shrink tumors or extend survival in people with advanced biliary tract cancers that have certain genetic changes (MAPK pathway alterations). About 66 participants whose cancer wo…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
Disease control OngoingThis phase 2 trial is testing whether adding either ramucirumab (a blood-vessel blocker) or merestinib (a cell-signal blocker) to standard chemotherapy (cisplatin + gemcitabine) can help people with advanced or metastatic biliary tract cancer live longer without their disease wor…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug aims to stop bile duct cancer from returning after surgery
Disease control OngoingThis global phase 3 trial is testing whether adding the immunotherapy drug rilvegostomig to standard chemotherapy can help prevent biliary tract cancer from coming back after surgery. About 757 people who had their cancer completely removed will receive either rilvegostomig or a …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug duo takes on tough liver cancers
Disease control OngoingThis study tests whether combining two drugs, domvanalimab and zimberelimab, can shrink or control advanced liver and bile duct cancers that have stopped responding to earlier treatments. About 58 adults with these cancers will receive the drug combination. The main goal is to se…
Phase 2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immune cells take on rare bile duct cancer in early trial
Disease control OngoingThis early-phase trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), can shrink advanced bile duct cancers. Four participants receive chemotherapy to prepare their immune system, then an infusion of their own TIL cells plus high-dose ald…
Phase 2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New cocktail of drugs shows promise for bile duct cancer
Disease control OngoingThis study tests a new drug combination for people with advanced biliary tract cancer (bile duct cancer) who haven't had treatment before. About 93 participants will receive either a standard chemotherapy plus two immunotherapy drugs, or the same plus an extra experimental drug. …
Phase 2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy targets Hard-to-Treat bile duct cancer
Disease control OngoingThis study tests whether combining two drugs—regorafenib (a targeted therapy) and durvalumab (an immunotherapy)—can help people with advanced biliary tract cancer that has stopped responding to chemotherapy. About 40 participants will receive both drugs to see if the combination …
Phase 1/2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New PET scan aims to spot hidden cancers with precision
Diagnosis OngoingThis study tests a special PET scan that uses a radioactive antibody (64Cu-M5A) to find cancers that produce a protein called CEA. The goal is to see if this scan can detect tumors that standard methods might miss. About 20 adults with CEA-positive cancers (such as breast, colon,…
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 07:57 UTC